Skip to main content
Premium Trial:

Request an Annual Quote

Seeking Nasdaq Listing, WaferGen Effects One-for-10 Reverse Stock Split

NEW YORK (GenomeWeb) – WaferGen Biosystems said after the close of the market on Monday that it has effected a one-for-10 reverse stock split as it seeks to list its shares on the Nasdaq Capital Market.

The company's shares will start trading on a split adjusted basis on the OTCBB when the markets open on July 1. The shares will trade for 20 days under the temporary trading symbol "WGBSD." The "D" indicates that the reverse stock split has occurred.

As a result of the reverse stock split, the number of WaferGen's issued and outstanding shares will contract to about 930,000 shares from 9.3 million shares. Earlier this month, the Fremont, Calif.-based firm disclosed its intentions to move to the Nasdaq following a $40 million public offering of its common stock.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.